Prescient Therapeutics Ltd - Asset Resilience Ratio
Prescient Therapeutics Ltd (PTX) has an Asset Resilience Ratio of 52.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Prescient Therapeutics Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Prescient Therapeutics Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Prescient Therapeutics Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Prescient Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Prescient Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$9.75 Million | 52.74% |
| Short-term Investments | AU$20.97K | 0.11% |
| Total Liquid Assets | AU$9.77 Million | 52.86% |
Asset Resilience Insights
- Very High Liquidity: Prescient Therapeutics Ltd maintains exceptional liquid asset reserves at 52.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Prescient Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Prescient Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Prescient Therapeutics Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Prescient Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.14% | AU$20.00K ≈ $14.15K |
AU$14.56 Million ≈ $10.30 Million |
-49.00pp |
| 2024-06-30 | 49.13% | AU$10.02 Million ≈ $7.09 Million |
AU$20.39 Million ≈ $14.43 Million |
-22.09pp |
| 2023-06-30 | 71.22% | AU$20.02 Million ≈ $14.17 Million |
AU$28.11 Million ≈ $19.89 Million |
+71.11pp |
| 2022-06-30 | 0.11% | AU$20.00K ≈ $14.15K |
AU$17.62 Million ≈ $12.47 Million |
+0.02pp |
| 2021-06-30 | 0.10% | AU$20.00K ≈ $14.15K |
AU$20.97 Million ≈ $14.84 Million |
-0.07pp |
| 2020-06-30 | 0.17% | AU$20.00K ≈ $14.15K |
AU$12.07 Million ≈ $8.54 Million |
-64.20pp |
| 2019-06-30 | 64.37% | AU$9.66 Million ≈ $6.83 Million |
AU$15.01 Million ≈ $10.62 Million |
+9.26pp |
| 2018-06-30 | 55.11% | AU$5.51 Million ≈ $3.90 Million |
AU$9.99 Million ≈ $7.07 Million |
-7.57pp |
| 2017-06-30 | 62.68% | AU$7.67 Million ≈ $5.42 Million |
AU$12.23 Million ≈ $8.65 Million |
+1.71pp |
| 2005-06-30 | 60.96% | AU$2.55 Million ≈ $1.80 Million |
AU$4.18 Million ≈ $2.96 Million |
-27.03pp |
| 2004-06-30 | 87.99% | AU$3.65 Million ≈ $2.58 Million |
AU$4.15 Million ≈ $2.94 Million |
+20.66pp |
| 2003-06-30 | 67.34% | AU$1.10 Million ≈ $778.32K |
AU$1.63 Million ≈ $1.16 Million |
-14.68pp |
| 2002-06-30 | 82.02% | AU$1.56 Million ≈ $1.11 Million |
AU$1.90 Million ≈ $1.35 Million |
-8.15pp |
| 2001-06-30 | 90.16% | AU$3.86 Million ≈ $2.73 Million |
AU$4.28 Million ≈ $3.03 Million |
-- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more